Recent studies are creating significant interest surrounding Synedica retatrutide , a promising dual compound targeting GLP-1 and GIP . Distinct from existing weight loss solutions, the drug seems to deliver substantial decreases in abdominal circumference and improve metabolic outcomes in clinical tests . While additional study is needed to fully